Differential expression of gp200-MR6 molecule in benign hyperplasia and down-regulation in invasive carcinoma of the breast
1996

Expression of gp200-MR6 in Breast Tumors

Sample size: 75 publication Evidence: moderate

Author Information

Author(s): AA Al-Tubuly, YA Luqmani, S Shousha, D Melcher, MA Ritter

Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital

Hypothesis

Does the expression of gp200-MR6 correlate with tumor progression in breast cancer?

Conclusion

The study found that gp200-MR6 is expressed in normal and benign breast tissues but is lost in invasive breast carcinomas.

Supporting Evidence

  • gp200-MR6 is expressed at high levels in normal breast tissue.
  • Expression of gp200-MR6 is lost in 71% of invasive carcinoma cases.
  • Benign hyperplasia shows heterogeneous expression of gp200-MR6.

Takeaway

This study looked at a molecule called gp200-MR6 in breast tissues and found that it is present in healthy and benign tissues but mostly absent in cancerous tissues.

Methodology

Immunohistochemical and biochemical analysis of fresh frozen tissue samples from breast tissues.

Limitations

The inability to detect gp200-MR6 in formalin-fixed paraffin-embedded tissues limited the sample size for benign hyperplasia.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication